Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zabicipril 是一种新型可口服的血管紧张转换酶抑制剂,是一种前药,在体内脱酯后具有抗高血压活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,960 | 现货 | ||
5 mg | ¥ 4,830 | 现货 | ||
10 mg | ¥ 6,880 | 现货 | ||
25 mg | ¥ 9,870 | 现货 | ||
50 mg | ¥ 13,800 | 现货 | ||
100 mg | ¥ 18,600 | 现货 |
产品描述 | Zabicipril is a novel orally available angiotensin-converting enzyme inhibitor, a prodrug with antihypertensive activity following in vivo de-esterification. |
体内活性 | We have investigated the acute effects of Zabicipril on systemic and renal haemodynamics in two groups of 8 sodium-replete normal men, aged 23 to 30 y and 65 to 74 y. Zabicipril 0.5 mg, 1 mg or 2.5 mg and a placebo were administered orally, at one-week intervals, in random order and in a double-blind fashion. Haemodynamic measurements were performed at baseline and every hour for 4 hours after intake of the drug or placebo. In the young men, zabicipril did not affect Q, heart rate (HR), systemic arterial pressure (AP) or GFR, but it did increase RPF at the 4th hour after the highest dose (from 540 to 653 ml.min-1.m-2). In the old men, zabicipril had similar actions, but the effect of the highest dose on RPF (from 355 to 415 ml.min-1.m-2) was less marked than in the young men. In the young and old men, the inhibition of ACE peaked at about 90% or more from the 2nd to the 4th hour after the highest dose of zabicipril. We conclude that, in normal men, zabicipril increases the renal fraction of cardiac output in the absence of a concomitant change in systemic haemodynamics. This specific effect of zabicipril on the kidney may be less important with advancing age.[1] |
分子量 | 416.51 |
分子式 | C23H32N2O5 |
CAS No. | 83059-56-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (132.05 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4009 mL | 12.0045 mL | 24.009 mL | 60.0226 mL |
5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL | 12.0045 mL | |
10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL | 6.0023 mL | |
20 mM | 0.12 mL | 0.6002 mL | 1.2005 mL | 3.0011 mL | |
50 mM | 0.048 mL | 0.2401 mL | 0.4802 mL | 1.2005 mL | |
100 mM | 0.024 mL | 0.12 mL | 0.2401 mL | 0.6002 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Zabicipril 83059-56-7 Endocrinology/Hormones RAAS Inhibitor inhibitor inhibit